1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Drugs In Development, 2022, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 10, 2, 40, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 12 molecules, respectively.
Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Spinal Cord Injury - Overview
- Spinal Cord Injury - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Spinal Cord Injury - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Spinal Cord Injury - Companies Involved in Therapeutics Development
- Spinal Cord Injury - Drug Profiles
- Spinal Cord Injury - Dormant Projects
- Spinal Cord Injury - Discontinued Products
- Spinal Cord Injury - Product Development Milestones
- Featured News & Press Releases
- Sep 17, 2022: NervGen Pharma presenting at upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting
- May 20, 2022: Birmingham research brings hope for spinal cord injury treatment
- May 18, 2022: NervGen hosting ppanel discussion with leading experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
- May 12, 2022: NervGen Pharma receives approval to proceed to the final dose cohort in phase 1 clinical trial of NVG-291
- Mar 31, 2022: NervGen presenting interim phase 1 clinical trial data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
- Mar 23, 2022: NervGen Pharma to present at 2022 virtual growth conference presented by Maxim Group
- Mar 15, 2022: NervGen Pharma receives approval from Safety Review Committee to proceed to second cohort in multiple ascending dose portion of phase 1 clinical trial of NVG-291
- Jan 10, 2022: NervGen Pharma announces intent to conduct groundbreaking spinal cord injury clinical trial in exclusive partnership with Shirley Ryan AbilityLab, 1-Ranked Hospital in Physical Medicine & Rehabilitation
- Dec 22, 2021: NervGen Pharma receives ethics board approval for multiple ascending dose portion of NVG-291 phase 1 trial
- Nov 04, 2021: NervGen presents additional phase 1 clinical trial data for NVG-291 at Neuroscience 2021 / safety review committee provides recommendation to proceed to multiple ascending dose portion of the trial
- Oct 27, 2021: NervGen Pharma announces spinal cord injury clinical advisory board
- Oct 18, 2021: NervGen presents interim phase 1 clinical trial data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 demonstrated to be well tolerated along with a favorable pharmacokinetic profile
- Sep 27, 2021: NervGen Pharma partners with Imeka to use novel neuroimaging technology in clinical trials
- Sep 12, 2021: NervGen Pharma presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
- Sep 08, 2021: Phase 2 Trial of MT-3921 initiated for treatment of spinal cord injury
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Spinal Cord Injury, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Spinal Cord Injury - Dormant Projects, 2022
- Spinal Cord Injury - Discontinued Products, 2022
- Number of Products under Development for Spinal Cord Injury, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 9 Meters Biopharma Inc
- AbbVie Inc
- AlaMab Therapeutics Inc
- Angion Biomedica Corp
- Aposcience AG
- Asha Therapeutics LLC
- AstraZeneca Plc
- Athersys Inc
- Axoltis Pharma SAS
- Axoneural Therapeutics Inc
- AXONIS Therapeutics Inc
- BioAxone BioSciences Inc
- Cellatoz Therapeutics Inc
- CellCure
- CSL Ltd
- Daewoong Pharmaceutical Co Ltd
- EUSOL Biotech Co Ltd
- GABA Therapeutics Inc
- Gene Therapy Research Institution Co Ltd
- Genervon Biopharmaceuticals LLC
- GNT Pharma Co Ltd
- Helixmith Co Ltd
- Hemostemix Inc
- Hibernaid Inc
- Histocell SL
- Hope Biosciences LLC
- Hopstem Biotechnology LLC
- iCELL Biotechnology Co Ltd
- Jazz Pharmaceuticals Plc
- Kidswell Bio Corp
- Kringle Pharma Inc
- Lineage Cell Therapeutics Inc
- Locate Bio Ltd
- Mapreg SAS
- Mitsubishi Tanabe Pharma Corp
- NervGen Pharma Corp
- NeuExcell Therapeutics Inc
- Neuroplast BV
- New World Laboratories Inc
- Novago Therapeutics AG
- Novartis AG
- Novoron Bioscience Inc
- NuNerve Pty Ltd
- Oligogen Inc
- Palisade Bio, Inc
- PharmatrophiX Inc
- Q Therapeutics Inc
- Q32 Bio Inc
- Radikal Therapeutics Inc
- RE-Stem Biotech Co Ltd
- ReNetX Bio
- RespireRx Pharmaceuticals Inc
- Rudacure Co Ltd
- S.Biomedics Co Ltd
- SanBio Co Ltd
- Shanghai Angecon Biotechnology Co Ltd
- Stand Up Therapeutics Co Ltd
- StemCyte Inc
- Stemedica Cell Technologies Inc
- Stemmatters Biotecnologia e Medicina Regenerativa SA
- Sumitomo Pharma Co Ltd
- TechnoPhage SA
- Truvitech LLC
- Tumorend LLC
- VersaPeutics Inc
- ZyVersa Therapeutics Inc
